XDWH:LSE:LSE-Xtrackers MSCI World Health Care UCITS ETF 1C (USD)

ETF | Others |

Last Closing

USD 57.3

Change

-0.13 (-0.23)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-1.75 (-0.94%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-3.13 (-2.62%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.02 (-0.12%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.12 (+0.87%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.45 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

-1.75 (-1.83%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.04 (-0.13%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

-1.75 (-1.04%)

USD 202.26B
0R24:LSE Intel Corp.

-0.81 (-3.45%)

USD 196.14B

ETFs Containing XDWH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.31% 71% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.31% 70% C- 69% C-
Trailing 12 Months  
Capital Gain 22.59% 66% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.59% 65% D 65% D
Trailing 5 Years  
Capital Gain 75.87% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.87% 80% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 9.39% N/A N/A 68% D+
Dividend Return 9.39% N/A N/A 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.12% N/A N/A 79% B-
Risk Adjusted Return 92.80% N/A N/A 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike